INmune Bio Inc expected to post a loss of 38 cents a share - Earnings Preview

Inmune Bio

28/07/2025 12:45

INmune Bio Inc INMB.OQ INMB.O is expected to  show a rise in quarterly revenue when it reports  results on July 30 (estimated) for the period ending June 30 2025

The Boca Raton Florida-based  company is expected to report revenue of $1.67 thousand, according to the mean estimate from 6 analysts, based on LSEG data.

‚ÄčLSEG's mean analyst estimate for INmune Bio Inc is for a loss of 38 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 2 "hold" and 1 "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ‚Äč

Wall Street's median 12-month price target for INmune Bio Inc is $7.00, about 61.3% above its last closing price of $2.71

Previous quarterly performance (using preferred earnings measure in US dollars). ‚Äč

QUARTER ENDING
STARMINESMARTESTIMATE¬ģ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.47
-0.47
-0.43
Beat
8.5
Dec. 31 2025
-0.54
-0.40
Beat
25.9
Sep. 30 2024
-0.48
-0.50
-0.60
Missed
-20.8‚Äč
Jun. 30 2024
-0.63
-0.63
-0.50
Beat
20.6
‚Äč‚ÄčMar. 31 2024
-0.53
-0.53
-0.61
Missed
-14
Dec. 31 2023
-0.44
-0.47
Missed
-6.8‚Äč
Sep. 30 2023
-0.39
-0.39
-0.48
Missed
-21.5
Jun. 30 2023
-0.39
-0.40
-0.36
Beat
9.2

This summary was machine generated July 28 at 11:45 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)